ASCO GI 2022 | What the future may hold for ctDNA in cancer screening and diagnosis

Naureen Starling, BSc, FRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK discusses the future possibilities for circulating tumor DNA (ctDNA) for cancer screening and diagnosis. ctDNA could be used to improve the utilization of current screening programs, perhaps used in a supplementary way or may even offer blood-based alternatives to replace certain screening programs. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022.